Company: AZN
Filing Date: 2025-10-22
Form Type: 6-K
Source: 0001654954-25-012040
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-10-22
Form: 6-K
Chunk 7
---
 Available at: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf . Accessed: October 2025.

21. Dupixent (dupilumab) US prescribing information. Available at: https://www.regeneron.com/downloads/dupixent_fpi.pdf . Accessed: October 2025.

22. Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). Available at: https://clinicaltrials.gov/ct2/show/NCT04851964 . Accessed: October 2025.

23. Zhang M, et al. Hypoxia induces the production of epithelial-derived cytokines in eosinophilic chronic rhinosinusitis with nasal polyps. Int Immunopharmacol. 2023;121:110559.

24. Li Y, et al . Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. J Immunol . 2018;200: 2253-2262.

25. Ying, S, O'Connor, B, Ratoff, J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005;174:8183-8190.

26. AstraZeneca Data on File. 2025. REF-278452.

27. Clinicaltrials.gov. Tezepelumab COPD Exacerbation Study (COURSE). Available at: https://clinicaltrials.gov/ct2/show/NCT04039113 . Accessed: October 2025.

28. Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING). Available at: https://clinicaltrials.gov/study/NCT05583227 . Accessed: October 2025.

29. AstraZeneca news release. Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-dr